These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical experience of cefotaxime (author's transl)].
    Author: Portier H, Carbon C, Boussougant Y, Destaing F.
    Journal: Nouv Presse Med; 1981 Feb 26; 10(8):607-11. PubMed ID: 6259603.
    Abstract:
    Seventeen septicaemia, 18 urinary tract infections, 13 acute bacterial pulmonary infections and 7 infections at various other site were treated with cefotaxime, and, in 48 cases, with cefotaxime alone. The pathogenic organisms were mainly enterobacteria: 19 E. coli, 10 Klebsiella, 8 Proteus, 2 Serratia, 1 Enterobacter, almost all of them having a MIC less than or equal to 1 mcg/ml. The route of administration used was the i.m. route in 33 cases and the i.v. route in 18 cases, both routes having been used in 4 patients. The mean dosage was 45 mg/kg/day. A cure was obtained in 49 cases were clinical and bacteriological results were interpretable (85,7% of cases). The cure rate was 80% in septicaemia, 88,2% in urinary infections and 91,6% in pulmonary infections. In 19 infections due to beta-lactamase producing strains of Gram-negative bacteria, the percentage of cure was 68,4%. The systemic and local tolerance was excellent. Cefotaxime is a very well tolerated and very effective antibiotic, even in prolonged treatment and even in monotherapy, at a mean dosage of 50 mg/kg/day.
    [Abstract] [Full Text] [Related] [New Search]